Reappraisal of GIP Pharmacology for Metabolic Diseases
Research output: Contribution to journal › Review › Research › peer-review
Glucagon-like peptide-1 (GLP-1) analogs are considered the best current medicines for type 2 diabetes (T2D) and obesity due to their actions in lowering blood glucose and body weight. Despite similarities to GLP-1, glucose-dependent insulinotropic polypeptide (GIP) has not been extensively pursued as a medical treatment for T2D. This is largely based on observations of diminished responses of GIP to lower blood glucose in select patients, as well as evidence from rodent knockout models implying that GIP promotes obesity. These findings have prompted the belief in some, that inhibiting GIP action might be beneficial for metabolic diseases. However, a growing body of new evidence - including data based on refined genetically modified models and improved pharmacological agents - suggests a paradigm shift on how the GIP system should be manipulated for metabolic benefits.
Original language | English |
---|---|
Journal | Trends in Molecular Medicine |
Volume | 22 |
Issue number | 5 |
Pages (from-to) | 359-76 |
Number of pages | 18 |
ISSN | 1471-4914 |
DOIs | |
Publication status | Published - May 2016 |
Externally published | Yes |
- Animals, Blood Glucose, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucagon-Like Peptide 1, Humans, Insulin, Metabolic Diseases, Mice, Obesity, Receptors, Gastrointestinal Hormone, Journal Article, Review
Research areas
ID: 186640138